Invitrall develops advanced diseases in vitro models that represent human genetic diversity that provides innovative solutions.
Invitrall has raised $250K in total funding. The most recent round was Pre-Seed. The last funding was announced in July 2024.
Invitrall's investors include GRID EXPONENTIAL.
Invitrall is headquartered in Curitiba, Brazil.
Invitrall develops advanced diseases in vitro models that represent human genetic diversity that provides innovative solutions.
Invitrall is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Invitrall — Funding & Investors." VCBacked, July 1, 2024, https://www.vcbacked.co/company/invitrall. Accessed August 15, 2026.
VCBacked. (2024). Invitrall — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/invitrall
{{cite web |title=Invitrall — Funding & Investors |url=https://www.vcbacked.co/company/invitrall |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated